Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 14/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | GRK2 | P25098 | 2/20 | 0.35 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17458560 | 1.00 | BRD4 (0.36) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17467748 | 1.00 | BRD4 (0.36) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17464752 | 0.93 | SMYD3 (0.39) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17464737 | 0.92 | BRD4 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17458496 | 0.92 | BRD4 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17464743 | 0.92 | BRD4 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17467766 | 0.92 | BRD4 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17467804 | 0.92 | BRD4 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17463938 | 0.88 | KCNH2 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 | |
| SCHEMBL17456742 | 0.88 | KCNH2 (0.37) | BRD4ROCK2ROCK1GRK2GRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701663-B2 | Sulfonamide retinoic acid receptor-related orphan receptor modulators and uses thereof | INNOV17 LLC (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | INNOV17 LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024056-A1 | SULFONAMIDE RETINOIC ACID RECEPTOR-RELATED ORPHAN RECEPTOR MODULATORS AND USES THEREOF | RARA, RARB, RXRA | BRD4 3959/4885ROCK2 4542/4885ROCK1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.